ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

US Judge Upholds Validity Of Merck's Vytorin Patent

By Peter Loftus Of DOW JONES NEWSWIRES A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (MRK) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years. In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable. Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017. Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable. Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday. On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said. A Mylan spokeswoman couldn't immediately be reached. Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million. Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
04/18/201515:02:033 Drug Stocks Leading the Charge Against Infectious Diseases
04/18/201510:02:03What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?
04/16/201508:03:02The Best Stock to Invest in Hep C
04/14/201513:30:00Phase III Trial of the Merck and NewLink Genetics Investigational...
04/14/201509:20:21Heat Biologics Is An Opportunity Among Soaring Immunotherapy...
04/14/201508:44:32The Growing Business Of Animal Healthcare
04/14/201507:00:00NewLink Genetics and Merck & Co Receives Vaccine Industry Excellence...
04/13/201521:12:18The New Dogs Of The Dow - Q1 2015
04/13/201518:02:26Merck CEO's 2014 Total Compensation Valued at $25 Million...
04/13/201517:26:06Statement of Changes in Beneficial Ownership (4)
04/13/201516:34:12Additional Proxy Soliciting Materials (definitive) (defa14a)
04/13/201516:33:18Proxy Statement (definitive) (def 14a)
04/13/201513:40:09Fitch Downgrades Merck
04/12/201515:56:23How the Hottest Biotech Sprouted in Iowa
04/12/201509:52:033 Best Dividend Stocks in Healthcare
04/11/201503:51:07Immunotherapy: Unleashing The Immune System To Decimate Cancer
04/09/201517:59:09Why Investors Shouldn't Worry About Explosive New Drug Pricing:...
04/09/201514:30:09Squabbles Over Testing Methods Hamper Search for Ebola Vaccine
04/09/201501:28:13Is Biogen A Buy? An Analysis Of Its Growth Drivers And Challenges
04/08/201516:50:52Why Advaxis Inc. Shares Soared Today

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad